These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23481032)

  • 1. Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence.
    Etzioni R; Gulati R
    Med Care; 2013 Apr; 51(4):304-6. PubMed ID: 23481032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening.
    Etzioni R; Gulati R; Cooperberg MR; Penson DM; Weiss NS; Thompson IM
    Med Care; 2013 Apr; 51(4):295-300. PubMed ID: 23269114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Counterpoint: Randomized trials provide the strongest evidence for clinical guidelines: The US Preventive Services Task Force and Prostate Cancer Screening.
    Melnikow J; LeFevre M; Wilt TJ; Moyer VA
    Med Care; 2013 Apr; 51(4):301-3. PubMed ID: 23481031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
    Carter HB
    BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American Cancer Society guideline for the early detection of prostate cancer: update 2010.
    Wolf AM; Wender RC; Etzioni RB; Thompson IM; D'Amico AV; Volk RJ; Brooks DD; Dash C; Guessous I; Andrews K; DeSantis C; Smith RA;
    CA Cancer J Clin; 2010; 60(2):70-98. PubMed ID: 20200110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer screening--the evidence, the recommendations, and the clinical implications.
    Chou R; LeFevre ML
    JAMA; 2011 Dec; 306(24):2721-2. PubMed ID: 22203543
    [No Abstract]   [Full Text] [Related]  

  • 8. Prostate Cancer Screening - A Perspective on the Current State of the Evidence.
    Pinsky PF; Prorok PC; Kramer BS
    N Engl J Med; 2017 Mar; 376(13):1285-1289. PubMed ID: 28355509
    [No Abstract]   [Full Text] [Related]  

  • 9. Risks of PSA screening now better understood.
    Peres J
    J Natl Cancer Inst; 2013 Nov; 105(21):1590-2. PubMed ID: 24142893
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
    Pron G
    Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.
    Qaseem A; Barry MJ; Denberg TD; Owens DK; Shekelle P;
    Ann Intern Med; 2013 May; 158(10):761-769. PubMed ID: 23567643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA testing for men at average risk of prostate cancer.
    Armstrong BK; Barry MJ; Frydenberg M; Gardiner RA; Haines I; Carter SM
    Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of modelling in the policy decision making process for cancer screening: example of prostate specific antigen screening.
    Getaneh AM; Heijnsdijk EA; de Koning HJ
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies.
    Gulati R; Feuer EJ; Etzioni R
    Am J Epidemiol; 2016 Jul; 184(2):140-7. PubMed ID: 27358266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
    Colditz GA
    Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts.
    Rove KO; Crawford ED
    World J Urol; 2012 Apr; 30(2):137-42. PubMed ID: 22116599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
    Tawfik A
    Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for Prostate Cancer: Recommendation Statement.
    Am Fam Physician; 2018 Oct; 98(8):Online. PubMed ID: 30277733
    [No Abstract]   [Full Text] [Related]  

  • 19. Screening for Prostate Cancer.
    Wolff T; Jadotte YJ
    Am Fam Physician; 2018 Oct; 98(8):537-538. PubMed ID: 30277736
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessing the efficacy of cancer screening.
    Jacklyn G; Bell K; Hayen A
    Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.